Biomedical applications of cysteine-rich proteins

来源 :The 6th International Conference on Nanoscience and Technolo | 被引量 : 0次 | 上传用户:gaylene
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Highly crosslinked proteins,including keratin and soyprotein containing 7%and 1.2%of cysteine respectively,were electrospun into three-dimensional(3D)ultrafine fibrous scaffolds for biomedical applications.
其他文献
Two-dimensional transition-metal dichalcogenide alloys have attracted intense attention due to their tunable band structure.ReSxSe(2-x)is unusual among the transition-metal dichalcogenide alloys becau
The synthesis of 2D graphene-like covalent bonded organic frameworks(sCOF)has attracted increasing interests recently.
As bone implant can have profound impacts on the host immune response,it is necessary to think in the perspective of immuno-modulation [1] and higher long-term survival rate,especially in the host wit
Conjugation of antigenic epitopes to nanoscale particulates has shown that the conjugate has ability to improve immune responses.
Cationized polymer(polycation)is one of the widely used nonviral vectors for siRNA delivery.However,the cytotoxicity is sometimes high and the transfection efficacy is much lower than viral vectors es
Near-infrared plasmonic nanoparticles demonstrate great potential in disease theranostic applications.
The insufficient cellular uptake of nanocarriers and their slow drug release have become major obstacles for achieving satisfactory anticancer outcomes in nano-medicine therapy.
The human mutT homologue MTH1,a nucleotide pool sanitizing enzyme,represents a vulnerability factor and an attractive target for anticancer therapy.
Although many multifunctional drug-loaded nanomaterials have been designed to increase drug delivery into tumor cells,only limited improvement has been achieved to overcome multi-layered stromal cell
Purpose-Peptides have emerged as promising cancer therapeutics characterized by low toxicity,high specificity,and ease of synthesis.The short half-life of peptide therapeutics stands as the most chall